The Study
Practical treatment with minimum maintenance dose of anti-thyroid drugs for prediction of remission in Graves' disease.
This study watched a group of people with Graves' disease and saw what happened when they stopped their medicine after taking a small dose for six months. It found that most stayed healthy, but it didn't test if the medicine itself caused that—just that it happened together.
Analysis score
Maximum 72 for a cohort study.
Where the score came from
Doctors gave thyroid medicine to people with Graves' disease, then slowly lowered the dose until it was very small. They stopped the medicine after 6 months of feeling normal.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 539 / 100
Quality score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Key takeaways
Summary
Based on the study abstract and findings.
- 1This means most people can stop medicine safely after 6 months of feeling fine — no need for expensive antibody tests unless TSAb is extremely high.
- 281% of patients stayed healthy for 2 years after stopping medicine.
- 3If their TSAb antibody level was over 2000% when they stopped, they almost always got sick again.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Endocrine journal
Year
2003
Authors
T. Kashiwai, Y. Hidaka, T. Takano, K. Tatsumi, Y. Izumi, Y. Shimaoka, H. Tada, K. Takeoka, N. Amino
Related Content
Claims (6)
Treatment with anti-thyroid drugs leads to long-term cessation of immune-mediated destruction of the thyroid gland in people with Graves' disease.
Patients with Graves' disease who stay in remission after stopping anti-thyroid drugs have the same treatment duration as those who relapse, indicating that how long the drugs were taken does not determine the outcome.
In patients with Graves' disease, stopping anti-thyroid medication after six months of low-dose treatment results in an 81% chance of remaining euthyroid at two years without further medication.
In patients with Graves' disease, those who remain in remission after stopping medication have lower levels of TBII and TSAb antibodies at the time of discontinuation than those who relapse, but the range of antibody levels overlaps so much that it cannot reliably predict which individuals will relapse.
Testing for TBII or TSAb antibodies when stopping thyroid medication does not improve the ability to predict whether Graves' disease will stay in remission, beyond knowing that the patient has been euthyroid for six months on low-dose medication.
In patients with Graves' disease who stop taking anti-thyroid drugs, a blood test showing TSAb levels above 2000% is linked to a higher chance of the disease returning.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.